StockData

OptimizeRx vs Paysign

OPRX and PAYS side by side, both in miscellaneous business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How OPRX and PAYS compare

Paysign is the larger company, worth 4.2 times as much as OptimizeRx ($554M against $131M).

On earnings, OptimizeRx is cheaper: it trades at 28.9× trailing earnings, against 37.7× for Paysign.

Paysign grew revenue faster over the last twelve months (46.8% versus −5.8% for OptimizeRx).

Paysign keeps more of each dollar of sales as profit, with a net margin of 15.7% compared with 4.7% at OptimizeRx.

Paysign scores higher on the StockData Score (14 against 10 for OptimizeRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricOPRXPAYS
Size and price
Market cap$131M$554M
Share price$6.94$9.81
Change, 1 year−54.3%92.0%
Change, 5 years−89.9%401%
Beta (5Y)1.50−0.02
Employees10480
StockData Score
Total score1014 (better)
Valuation score3 (better)2
Growth score25 (better)
Performance score24 (better)
Health score33
Dividend score00
Valuation
P/E28.9× (better)37.7×
P/S1.3× (better)5.5×
P/B1.0× (better)9.2×
EV/EBITDA8.3× (better)20.1×
P/FCF7.1× (better)7.5×
PEG–0.44
FCF yield14.0% (better)13.3%
Fair value$9.96$9.74
Margin of safety30.4% (better)−0.70%
Growth
Revenue growth (TTM)−5.8%46.8% (better)
Revenue growth, 5Y average20.4%27.7% (better)
Net income growth (TTM)–133%
EPS growth (TTM)–117%
Profitability
Gross margin73.2% (better)61.0%
Operating margin11.1%17.0% (better)
Net margin4.7%15.7% (better)
FCF margin18.6%73.0% (better)
Return on equity3.7%30.8% (better)
Return on invested capital5.8%35.2% (better)
Financial health
Debt / equity0.150.09 (better)
Net debt / EBITDA−0.33−0.84
Interest coverage2.3×–
Current ratio5.58 (better)1.14
Altman Z-score2.82 (better)2.04
Piotroski F-score8 (better)7
Dividends and buybacks
Buyback yield–0.00%
Shareholder yield0.00%0.00%
Ownership
Held by institutions59.6%53.6%
Held by insiders19.4%53.5%
Insider net buying, 12 months−$18.8K (better)−$8.4M
Short interest, % of float7.8%9.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.